| Primary | Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose | IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | At 2 hours after first dose of study drug | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00093.15(80.4 to 100.0)
- OG00131.05(10.3 to 56.9)
|
|
| |
| Primary | Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug | IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Least Squares Mean | Standard Error | Percentage/Hour | | 4 to 72 Hours after last dose of study drug | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 0.5 hours after first dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 1 hour after first dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 4 hours after first dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 8 hours after first dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 24 hours after first dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 0 hour before last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 2 hours after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 4 hours after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 8 hours after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 24 hours after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 48 hours after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 72 hours after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 120 hours - Day 5 after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 168 hours - Day 7 after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose | IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. | Intent-to-treat analysis set: included patients who were randomised to a treatment group, received at least one dose of study drug, and contributed post baseline data. | Posted | | Median | Inter-Quartile Range | Percentage | | 240 hours - Day 10 after last dose | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1) | FEV1 is measured by Spirometry, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Post 6-week Treatment: FEV1 | FEV1 is measured by Spirometry, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC) | FVC is measured by Spirometry, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Post 6-week Treatment: FVC | FVC is measured by Spirometry, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio) | FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Ratio | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio | FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Ratio | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75) | FEF25-75 is measured by Spirometry, the unit is Liter/Second. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter/second | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75 | FEF25-75 is measured by Spirometry, the unit is Liter/Second. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter/second | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC) | FRC is measured by Body Box Plethysmography, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: FRC | FRC is measured by Body Box Plethysmography, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC) | TLC is measured by Body Box Plethysmography, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: TLC | TLC is measured by Body Box Plethysmography, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Residual Volume (RV) | RV is measured by Body Box Plethysmography, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: RV | RV is measured by Body Box Plethysmography, the unit is Liter. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE) | VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liter/minute | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: VE | VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liter/minute | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR) | RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Breaths/minute | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: RR | RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Breaths/minute | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Tidal Volume (VT) | VT is measured by Body Box Plethysmography, the unit is Liter/Minute. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Liters/minute | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: VT | VT is measured by Body Box Plethysmography, the unit is Liter/Minute. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Liters/minute | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB) | DLCOSB is measured by Body Box Plethysmography, the unit is Percent. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Percent | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB | DLCOSB is measured by Body Box Plethysmography, the unit is Percent. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Percent | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF) | EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Percent | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: EF | EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Percent | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | NT-proBNP is measured by clinical lab, the unit is pg/mL. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | pg/ml | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP | NT-proBNP is measured by clinical lab, the unit is pg/mL. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | pg/ml | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2) | SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 1 baseline data. | Posted | | Mean | Standard Deviation | Percent | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |
| Secondary | Cardiopulmonary Parameters Post 6-week Treatment: SpO2 | SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. | Safety analysis set: included all patients who received at least 1 dose of study drug and contribute to the week 6 post treatment data. | Posted | | Mean | Standard Deviation | Percentage | | 6-week post treatment | | | | ID | Title | Description |
|---|
| OG000 | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses | | OG001 | Clopidogrel | Clopidogrel 600 mg loading dose followed by 75 mg od, plus ticagrelor placebo loading and bd maintenance doses | | OG002 | Placebo | Ticagrelor 180 mg placebo loading dose followed by 90 mg bd, plus clopidogrel placebo loading and od maintenance doses |
| |